Marstacimab experiences in adolescents and adults with hemophilia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational patient registry enrolls adolescents (12–17) and adults (≥18) with hemophilia A or B who are prescribed marstacimab for routine prophylaxis. Participants complete the Marstacimab-Patient Preference Questionnaire (M-PPQ) after one month to record injection-route preferences and the Hemophilia Treatment Experience Measure (Hemo-TEM) after six months to measure treatment burden. The registry will also collect clinical data, including annualized bleeding rates, to explore real-world bleeding outcomes during marstacimab prophylaxis. Data are collected at participating hospitals in China during routine clinical visits without altering prescribed care.

Why it matters

Who can join: the full rules

Inclusion Criteria:

\- Participants with a diagnosis of hemophilia A or hemophilia B eligible to receive prophylaxis.

Clinical physicians prescribe marstacimab for routine prophylaxis treatment of hemophilia patients based on the actual conditions of the patients and in accordance with the approved indications of marstacimab.

Adolescent patients(12 to less than 18 years) and adult (18 years and older) patients.

Signed consent obtained before the study, participant or legally authorized representative, or participant's caregiver capable of giving signed informed consent.

Exclusion Criteria:

\- Those who are unable to complete at least one month follow-up based on the investigator's judgment.

Severe impairment of speech, vision, memory or cognition that affects communication and ability to complete questionnaires and follow-up visits.

Women of childbearing age who plan to become pregnant within the next 2 months, as well as women who are pregnant or breastfeeding.

Patients are participating in other clinical trials. There are other conditions that the investigator deems unsuitable for participation in this study.

Where it's running

• The First Affiliated Hospital of Xiamen University
  Xiamen, Fujian, China Recruiting
• Institute of haematology and Blood diseases hospital
  Tianjin, Tianjin Municipality, China Recruiting

Study contacts

• Study coordinator: renchi yang, MD
• Email: yangrenchi@ihcams.ac.cn
• Phone: 022-23608174

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Marstacimab for mild to moderate hemophilia A or B in people without inhibitors

  This study tests whether weekly injections of marstacimab can reduce bleeding in adolescents and adults with mild to moderate hemophilia A or B who don’t have inhibitors.

  Recruiting Phase 3 Pfizer · Flowood, Mississippi · NCT07923981

• Personalized Hemophilia Care Through Telemedicine and Adherence Monitoring

  This study tests a telemedicine-based program to closely monitor bleeding, ensure patients stick to their treatment plan, and personalize care for adults with hemophilia who use a smartphone.

  Recruiting Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Milan · NCT07867834

• Checks how well the Figure-of-Eight Walk and Weight-Bearing Lunge tests measure movement in adults with hemophilia

  This observational study tests two movement tests to see if they reliably reflect mobility in adults with hemophilia who have a history of joint bleeding.

  Recruiting Yuzuncu Yil University · Van · NCT07851922

• Multimodal Telerehabilitation vs Face-to-Face Care for Adults with Hemophilia and Chronic Pain

  This trial tests whether a 6-week telerehabilitation program combining pain education and therapeutic exercise works as well as in-person care for adults with hemophilia and chronic pain.

  Recruiting University of Chile · Santiago, Santiago Metropolitan · NCT07682519

• PCC treatment for hemophilia A patients with inhibitors

  This trial tests whether giving prothrombin complex concentrate (PCC) during bleeding episodes can stop bleeds in people aged 12–65 with hemophilia A who have inhibitors.

  Recruiting Phase 4 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07406139

• Fitusiran prophylaxis for boys aged 1 to under 12 with severe hemophilia A or B

  This study tests whether fitusiran given as prophylaxis can reduce bleeding in boys aged 1 to under 12 with severe hemophilia A or B, with or without inhibitors.

  Recruiting at 37 sites Phase 3 Sanofi · Los Angeles, California and 36 other locations · NCT07285460

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.